Endocrine Abstracts

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the efficacy of dapagliflozin in type 2 diabetic patients. We evaluated the efficacy and safety of body weight reduction of dapagliflozin in real practice with type 2 diabetes in Korea.Methods: This is a retrospective, observational study, data from 61 patients ...